Literature DB >> 1736178

Cognitive functioning in cancer patients: effect of previous treatment.

C A Meyers1, J L Abbruzzese.   

Abstract

Neuropsychological analysis of 47 cancer patients with widely metastatic disease and significant previous treatment indicated that 34% had cognitive deficits. Previous treatment with biologic response modifiers was associated with a 53% frequency of cognitive abnormalities, whereas only 18% of patients who were never treated with biologics had such impairments. The possibility that neurobehavioral abnormalities will result from metastatic disease and treatment regimens is an important factor in determining the risks and benefits of therapy.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1736178     DOI： 10.1212/wnl.42.2.434

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  15 in total

Review 1.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

2.  Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?

Authors:  Fay J Hlubocky; Greg A Sachs; Eric R Larson; Halla S Nimeiri; David Cella; Kristen E Wroblewski; Mark J Ratain; Jeffery M Peppercorn; Christopher K Daugherty
Journal:  J Clin Oncol       Date:  2018-07-09       Impact factor: 44.544

3.  Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function.

Authors:  S B Schagen; H L Hamburger; M J Muller; W Boogerd; F S van Dam
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

4.  MEK1/2 inhibition suppresses tamoxifen toxicity on CNS glial progenitor cells.

Authors:  Hsing-Yu Chen; Yin Miranda Yang; Ruolan Han; Mark Noble
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

Review 5.  Inflammation, Self-Regulation, and Health: An Immunologic Model of Self-Regulatory Failure.

Authors:  Grant S Shields; Wesley G Moons; George M Slavich
Journal:  Perspect Psychol Sci       Date:  2017-07-05

6.  Measuring Self-Reported Cancer-Related Cognitive Impairment: Recommendations from the Cancer Neuroscience Initiative Working Group.

Authors:  Ashley M Henneghan; Kathleen Van Dyk; Tara Kaufmann; Rebecca Harrison; Christopher Gibbons; Cobi Heijnen; Shelli R Kesler
Journal:  J Natl Cancer Inst       Date:  2021-02-26       Impact factor: 13.506

7.  CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo.

Authors:  Joerg Dietrich; Ruolan Han; Yin Yang; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2006

8.  Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats.

Authors:  Gouda K Helal; Abdulaziz M Aleisa; Omayma K Helal; Salim S Al-Rejaie; Abdulaziz A Al-Yahya; Abdulhakeem A Al-Majed; Othman A Al-Shabanah
Journal:  Oxid Med Cell Longev       Date:  2009 Jan-Mar       Impact factor: 6.543

9.  Development of an item bank for computerized adaptive testing of self-reported cognitive difficulty in cancer patients.

Authors:  Linda Dirven; Martin Jb Taphoorn; Mogens Groenvold; Esther Jj Habets; Neil K Aaronson; Thierry Conroy; Jaap C Reijneveld; Teresa Young; Morten Aa Petersen
Journal:  Neurooncol Pract       Date:  2017-01-19

10.  Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system.

Authors:  Ruolan Han; Yin M Yang; Joerg Dietrich; Anne Luebke; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2008-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.